Partner Research Programs

Funder – NIH/NIMHD

Title – Peer Versus Adult-Led HIV Prevention for Juvenile Offenders: Effectiveness and Costs

Description

A randomized controlled trial comparing the effectiveness and cost of different types of intervention facilitators in order to identify the most effective and sustainable way to implement the PHAT Life program within juvenile justice settings. Karen Bernstein is a collaborating physician.

Funder – Global Blood Therapeutics

Title – A Phase 3 Double Blind Randomized Placebo Controlled Multi Center Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Funder – Incyte

Title – A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic and Biological Activity of INCB059872 in Subjects with Sickle Cell Disease

Funder – Global Blood Therapeutics

Title – A Phase 2A open Label, Multiple Dose Study Evaluate the Pharmacokinetics, Safety, Tolerability and Exploratory Treatment of GBT440 in Adolescents with SCD- Part B

Funder – Global Blood Therapeutics

Title – A Phase 2A Open Label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, tolerability and Exploratory Treatment of GBT440 in Adolescents with SCD- Part A

Funder – US Dept of Agriculture (Natl Inst of Food & Agriculture)(fmr CREES)

Title – Rosemary as a Food Preservative: Implications for Gastrointestinal Health

Colonization and Infection in Children with Multi-drug resistant Gram Negative Bacteria: A Comparative Study of Taxonomy, Risk Factors and outcomes

Description

This is a study of  ESBL- positive,  gram negative organisms  in children in several Chicago hospitals, and their molecular characteristics. UIC is one of the local participating institutions.

Funder – NIH

Title – Non-Covalent Nrf2 Activators for the Treatment of Chronic Wounds

Description

Chronic, non-healing wounds of the skin are serious medical complications that affect over 6.5 million Americans, especially older adults. These wounds include pressure sores, diabetic foot ulcers and venous ulcers. There are numerous surgical and dressing treatments for these wounds, but because there are over 70,000 lower-limb amputations each year arising from these wounds, it is clear that new treatments are needed. Strikingly, there are almost no pharmaceutical therapies to accelerate healing of chronic wounds. A major contributor to chronic wounds is a prolonged inflammatory state, and reducing inflammation may be a way to accelerate healing of chronic wounds. Unfortunately, many commonly used anti-inflammatory drugs hinder chronic wound healing; thus, new ways of reducing inflammation are needed. An essential factor in wound healing and an important regulator of inflammation is Nrf2, a transcription factor that induces many cytoprotective and antioxidant genes. As seen in other inflammatory disorders, activating Nrf2 could be a useful therapeutic strategy to treat chronic skin wounds. There are a number of covalent Nrf2 activators, but they are not selective for Nrf2, which is problematic because some of the off-target effects of these molecules are at proteins that hinder chronic wound healing. Thus, pharmacologic activation of Nrf2 with non-covalent small molecules will accelerate wound healing, which could lead to new therapeutics to treat chronic wounds. Our lab, in collaboration with Drs. DiPietro and Reddy labs at UIC, are using metabolism and pharmacokinetics studies, to develop high-affinity, metabolically stable, in vivo probes of Nrf2 activation for chronic wounds. These experiments are significant because they will develop novel in vivo probes of non-covalent Nrf2 activation, and they are innovative because they will open up new therapeutic strategies to treat chronic wounds.

Funder – US Dept of Health & Human Services (CDC)

Title –  SIP 14-022 Global and Territorial Health Research Collaborating Center: Illinois PRC

Title – Patient Perceptions about Sensitive Healthcare Questions